Zenas makes big bet on MS drug, striking $2B licensing deal with InnoCare
8th October 2025 Uncategorised 0Eying a multiple sclerosis drug that it has tabbed with peak annual sales potential of $12 billion in the U.S. alone, Zenas BioPharma has struck a licensing deal with China-based InnoCare Pharma that could be worth more than $2 billion.
More: Zenas makes big bet on MS drug, striking B licensing deal with InnoCare
Source: fierce